Albert Marchio News Today

Management with embattled drug maker Fresh Tracks Therapeutics Inc. (Nasdaq: FRTX), who have spent weeks trying to drum up support for a plan that would see the company dissolved and liquidated, now say they don’t think they have enough shareholder backing for that plan.

Fresh Tracks Therapeutics Inc. shareholders are set to vote this month to dissolve the company, a move that the drug developer expects to result in $5M-$7M returned to shareholders.

BOULDER — It’s been a wild ride over the past year or so for Fresh Tracks Therapeutics Inc., which plans to dissolve, liquidate and eliminate its workforce after failing to find a buyer or merger partner.